Blockade by 1,3-dipropyl-8-cyclopentylxanthine (CPX) of purine protection against kainate neurotoxicity

Brain Res. 1994 May 2;644(2):339-42. doi: 10.1016/0006-8993(94)91700-0.

Abstract

The adenosine A1 receptor selective antagonist 1,3-dipropyl-8-cyclopentylxanthine (CPX) has been administered systemically to rats together with the neurotoxin kainic acid. At the lower doses of CPX tested, 10 and 50 micrograms/kg, which were sufficient to prevent the neuroprotective activity of exogenous agonists, there was no exacerbation of the neuronal damage. At 250 micrograms/kg, some enhancement of damage was found, which was also produced by 8-(p-sulphophenyl)theophylline, a non-selective xanthine which does not cross the blood-brain barrier. The results are consistent with the involvement of a central A1 receptor in the neuroprotective activity of purines, and suggest that blockade of a peripheral adenosine receptor, possibly of the A2 type, may increase neuronal damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Kainic Acid / antagonists & inhibitors*
  • Kainic Acid / toxicity
  • Male
  • Nerve Degeneration / drug effects
  • Phenylisopropyladenosine / pharmacology
  • Purinergic P1 Receptor Antagonists
  • Purines / antagonists & inhibitors*
  • Purines / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Purinergic P1 / drug effects
  • Theophylline / analogs & derivatives
  • Theophylline / pharmacology
  • Xanthines / pharmacology*

Substances

  • Purinergic P1 Receptor Antagonists
  • Purines
  • Receptors, Purinergic P1
  • Xanthines
  • Phenylisopropyladenosine
  • 8-(4-sulfophenyl)theophylline
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Theophylline
  • 8-phenyltheophylline
  • Kainic Acid